Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

Journal of Clinical Oncology

Volumn 28, Issue 2, 2010, Pages 222-231

  Kurian, Allison W ^a   Sigal, Bronislava M ^a   Plevritis, Sylvia K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MONTE CARLO METHOD; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; RISK REDUCTION; SENSITIVITY ANALYSIS; BREAST TUMOR; CAUSE OF DEATH; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; OVARY TUMOR; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CAUSE OF DEATH; DECISION SUPPORT TECHNIQUES; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASTECTOMY; MIDDLE AGED; MONTE CARLO METHOD; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; RISK REDUCTION BEHAVIOR;

EID: 74949118129     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.7991     Document Type: Article

References (76)

1. John EM, Miron A, Gong G, et al: Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298:2869-2876, 2007
2. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003
3. National Comprehensive Cancer Network. Genetic Familial High-Risk Assessment: Breast and Ovarian. V. 1.2009. http://www.nccn.org/
4. Saslow D, Boetes C, Burke W, et al: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75-89, 2007
5. Domchek SM, Friebel TM, Neuhausen SL, et al: Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncol 7:223-229, 2006
6. Eisen A, Lubinski J, Klijn J, et al: Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol 23:7491-7496, 2005
7. Finch A, Beiner M, Lubinski J, et al: Salpingooophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296:185-192, 2006
8. Kauff ND, Domchek SM, Friebel TM, et al: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol 26:1331-1337, 2008
9. Rebbeck TR, Friebel T, Lynch HT, et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 22:1055-1062, 2004
10. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004
11. Kuhl CK, Schrading S, Leutner CC, et al: Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23:8469-8476, 2005
12. Leach MO, Boggis CR, Dixon AK, et al: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 365:1769-1778, 2005
13. Warner E, Plewes DB, Hill KA, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325, 2004
14. Bresser PJ, Seynaeve C, Van Gool AR, et al: The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy. Eur J Cancer 43:95-103, 2007
15. Robson M, Hensley M, Barakat R, et al: Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 89:281-287, 2003
16. Rocca WA, Bower JH, Maraganore DM, et al: Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69:1074-1083, 2007
17. Rocca WA, Grossardt BR, de Andrade M, et al: Survival patterns after oophorectomy in premenopausal women: A population-based cohort study. Lancet Oncol 7:821-828, 2006
18. Staton AD, Kurian AW, Cobb K, et al: Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 7:179-186, 2008
19. Plevritis SK, Kurian AW, Sigal BM, et al: Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295:2374-2384, 2006
20. Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25: 1329-1333, 2007
21. Evans DG, Shenton A, Woodward E, et al: Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 8:155, 2008
22. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998
23. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003
24. Metcalfe K, Lynch HT, Ghadirian P, et al: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335, 2004
25. Kramer JL, Velazquez IA, Chen BE, et al: Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 23:8629-8635, 2005
26. Brohet RM, Goldgar DE, Easton DF, et al: Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25:3831-3836, 2007
27. Haile RW, Thomas DC, McGuire V, et al: BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 15:1863-1870, 2006
28. Jernström H, Loman N, Johannsson OT, et al: Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer 41:2312-2320, 2005
29. Lee E, Ma H, McKean-Cowdin R, et al: Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: Results from a population-based study. Cancer Epidemiol Biomarkers Prev 17:3170-3178, 2008
30. McGuire V, Felberg A, Mills M, et al: Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 160:613-618, 2004
31. McLaughlin JR, Risch HA, Lubinski J, et al: Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. Lancet Oncol 8:26-34, 2007
32. Milne RL, Knight JA, John EM, et al: Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14:350-356, 2005
33. Modan B, Hartge P, Hirsh-Yechezkel G, et al: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345:235-240, 2001
34. Narod SA, Dubé MP, Klijn J, et al: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773-1779, 2002
35. Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339:424-428, 1998
36. Whittemore AS, Balise RR, Pharoah PD, et al: Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91:1911-1915, 2004
37. Chappuis PO, Nethercot V, Foulkes WD: Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18:287-295, 2000
38. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, et al: BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 13:7357-7362, 2007
39. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
40. Colditz GA, Willett WC, Stampfer MJ, et al: Menopause and the risk of coronary heart disease in women. N Engl J Med 316:1105-1110, 1987
41. Melton LJ 3rd, Khosla S, Malkasian GD, et al: Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 18:900-905, 2003
42. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005
43. Plevritis SK, Sigal BM, Salzman P, et al: A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr 36:86-95, 2006
44. Atchley DP, Albarracin CT, Lopez A, et al: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282-4288, 2008
45. National Comprehensive Cancer Network. Breast Cancer: V. 1.2009. http://www.nccn.org/
46. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123, 2007
47. Stolier AJ, Corsetti RL: Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation. Am Surg 71:1031-1033, 2005
48. National Comprehensive Cancer Network. Ovarian Cancer: V. 2.2009. http://www.nccn.org/
49. Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80-87, 2009
50. Rebbeck TR, Friebel T, Wagner T, et al: Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 23:7804-7810, 2005
51. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
52. Eisen A, Lubinski J, Gronwald J, et al: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100:1361-1367, 2008
53. Armstrong K, Schwartz JS, Randall T, et al: Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: A decision analysis. J Clin Oncol 22:1045-1054, 2004
54. Parker WH, Broder MS, Liu Z, et al: Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 106:219-226, 2005 55. Berkeley Mortality Database: http://www.demog.berkeley.edu/~bmd/
55. Centers for Disease Control, National Vital Statistics System, Worktable 292R. Death rates for 358 selected causes by 5-year age groups, race, and sex: United States, 1999-2004. http://www.cdc.gov/nchs/data/dvs/mortfinal2004- worktable292r.pdf
56. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017-2022, 2008
57. Peele PB, Siminoff LA, Xu Y, et al: Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decis Making 25:301-307, 2005
58. Sweeney KJ, Ryan E, Canney M, et al: Justifying adjuvant chemotherapy in breast cancer: A survey of women and healthcare professionals. Eur J Surg Oncol 33:838-842, 2007
59. Goldstein LJ, Gray R, Badve S, et al: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008
60. Anderson K, Jacobson JS, Heitjan DF, et al: Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144:397-406, 2006
61. Grann VR, Jacobson JS, Thomason D, et al: Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: An updated decision analysis. J Clin Oncol 20:2520-2529, 2002
62. Lee JM, Kopans DB, McMahon PM, et al: Breast cancer screening in BRCA1 mutation carriers: Effectiveness of MR imaging - Markov Monte Carlo decision analysis. Radiology 246:763-771, 2008
63. Schrag D, Kuntz KM, Garber JE, et al: Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336:1465-1471, 1997
64. van Roosmalen MS, Verhoef LC, Stalmeier PF, et al: Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: A more prominent role for oophorectomy. J Clin Oncol 20:2092-2100, 2002
65. Kuhl CK, Schrading S, Bieling HB, et al: MRI for diagnosis of pure ductal carcinoma in situ: A prospective observational study. Lancet 370:485-492, 2007
66. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002
67. Gronwald J, Tung N, Foulkes WD, et al: Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 118: 2281-2284, 2006
68. Jones LP, Li M, Halama ED, et al: Promotion of mammary cancer development by tamoxifen in a mouse model of BRCA1-mutation-related breast cancer. Oncogene 24:3554-3562, 2005
69. King MC, Wieand S, Hale K, et al: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251-2256, 2001
70. Sacchini V, Pinotti JA, Barros AC, et al: Nipple-sparing mastectomy for breast cancer and risk reduction: Oncologic or technical problem? J Am Coll Surg 203:704-714, 2006
71. Berrington de Gonzalez A, Berg CD, Visvanathan K, et al: Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 101:205-209, 2009
72. Ashworth A: A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785-3790, 2008
73. Kurian AW, Hartman AR, Mills MA, et al: Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: An initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expect 8:221-233, 2005
74. Nekhlyudov L, Bower M, Herrinton LJ, et al: Women's decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr 35:55-60, 2005
75. Uyei A, Peterson SK, Erlichman J, et al: Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: A single-institution study. Cancer 107:2745-2751, 2006
76. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001